FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Highlighting the potential of CG1/A2-targeting CAR T cells as a novel immunotherapy approach in myeloid malignancies.
연구 도서관으로 돌아가기
cathepsin G signal peptideCG1

Highlighting the potential of CG1/A2-targeting CAR T cells as a novel immunotherapy approach in myeloid malignancies.

May 16, 2026
Share

원본 논문

T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.

Yan Jun et al.Leukemia2025
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 위의 원본 논문에서 발견한 결과를 피테이드 연구 커뮤니티에게 이해하기 쉬운 언어로 분해합니다. 우리의 목표는 가장 중요한 사항을 강조하는 것입니다 — 실용적 의미, 증거의 강도, 그리고 현재 진행 중인 연구에 대한 의미.

Novel CAR T Cells Targeting Cathepsin G Signal Peptide Show Promise in Leukemia Treatment

Published: May 16, 2026 | Source: Leukemia (2025) | Category: cathepsin G signal peptide, CG1

Overview

A recent study published in Leukemia reveals the potential of chimeric antigen receptor (CAR) T cells targeting a specific signal peptide derived from cathepsin G (CG), known as CG1. This research offers new hope for treating acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) by leveraging an innovative immunotherapy approach.

Study Background

Immunotherapies have revolutionized cancer treatment, but the development of effective targets in myeloid malignancies has been challenging. The study builds on previous research where a T cell receptor mimic antibody targeting CG1 was developed and shown to be safe and efficacious against AML and CML. This new work aims to extend these findings by engineering CAR T cells that can recognize and target the same HLA-A2-restricted signal peptide, CG1.

What the Research Found

Researchers engineered CAR T cells using a T cell receptor mimic (TCR-m) specific for CG1/A2 complexes. These modified CAR T cells demonstrated high affinity for both CG1/A2 monomers and leukemia cells expressing this complex. The study showed that these CAR T cells were effective in preclinical models of AML and CML, indicating their potential as a therapeutic tool against these diseases.

What This Means for Peptide Users

While the findings are promising, it is important to note that this research has only been conducted in preclinical settings. For peptide users, particularly those involved in immunotherapy development or clinical trials, the study highlights a new direction in targeting myeloid malignancies through specific signal peptides. However, further validation and clinical testing are necessary before these CAR T cells can be used in patient care.

Limitations and Caveats

The primary limitation of this research is its preclinical nature; no human subjects have been involved yet. Additionally, the study focuses on HLA-A2-restricted CG1/A2 complexes, which limits applicability to patients with this specific genetic marker. The safety and efficacy profiles in humans remain unknown until clinical trials are conducted.

How This Compares to Previous Research

This work builds upon earlier studies that established the feasibility of targeting CG1 using TCR-m antibodies. Unlike those previous efforts, however, this study introduces a novel approach by utilizing CAR T cells engineered with the same specificity. While both methods show promise in preclinical settings, the use of CAR T cells may offer advantages such as enhanced persistence and anti-tumor activity.

Our Analysis

PeptideVault views this research positively but emphasizes the need for caution due to its preliminary stage. The innovative approach of targeting a signal peptide with CAR T cells represents an exciting development in cancer immunotherapy, particularly for myeloid malignancies where effective targets have been scarce. However, rigorous clinical validation is essential before these findings can be translated into practical medical applications.

Key Takeaways

  • Novel Target: CG1/A2 complexes represent a promising new target for CAR T cell therapy.
  • Preclinical Success: The study demonstrates efficacy in preclinical models of AML and CML.
  • Clinical Validation Needed: Further research is required to confirm safety and effectiveness in human patients.

Original Source

Citation: Yan Jun, Shi Chunhua, Yang Guojun et al. (2025). T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.. Leukemia. DOI: 10.1038/s41375-025-02652-0

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

이 분석은 Peptide Contacts 연구 팀에 의해 작성되었습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하기 위해 원본 논문 전체 방법론 및 데이터는 여기에서 확인하실 수 있습니다. 원래 출판물은 {source}에서 확인하실 수 있습니다. PubMed.

Comments

Sign in to join the discussion

이 분석은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.